SERUM FERRITIN IN PATIENTS WITH APLASTIC ANEMIA RECEIVING COMBINED IMMUNOSUPPRESSIVE THERAPY.
(Abstract release date: 05/21/15)
EHA Library. Fidarova Z. 06/12/15; 102906; PB1703
Disclosure(s): Research Center of Hematology of Russian Ministry of Healthchemotherapy of hemoblastoses and bone marrow transplantation
Dr. Zalina Fidarova
Contributions
Contributions
Abstract
Abstract: PB1703
Type: Publication Only
Background
Iron metabolism disorders in patients with AA are not only related to disease pathogenesis but to regular red blood cells (RBC) transfusions.
Aims
Analyze iron parameters before immunosupressive therapy, in time of it (meaning RBC transfusions dependence retained) and in remission phase.
Methods
A total of 85 patients from 18 to 65 years old were enrolled: 41 males and 44 females at age from 18 to 65 years old. Patients were followed up from 1 month to 3 years. Severe forms of AA were detected in 59 patients, non-severe in 26 pts. All patients received immunosupressive therapy (ATG + cyclosporine). Serum ferritin level (SF) was applied as the main iron overload (IOL) indicator (N 11-160 ng/ml). Depending on obtained results all patients were divided into 3 groups. Group 1 patients had SF evaluation prior to combined immunosupressive therapy (n = 47), these patients were split into subgroups 1A and 1B: 1A subgroup patients (n = 16) received < 20 transfusions in 1-4 months prior to the study, 1B subgroup patients (n = 31) received > 20 transfusions in 2-19 months prior to the study. Group 2 patients (n = 20) retained long term RBC transfusion dependence in spite of continued immunosupressive therapy. Group 3 patients (n = 20) demonstrated good immunosuppressive therapy response, therefore developed significant hematological improvement and became transfusion independent.
Results
In patients of 1A subgroup SF median was 303 ng/ml (range 40-1483 ng/ml), in 1B Group - 722 ng/ml (range 105-4950 ng/ml) with significant difference between SF levels received (p = 0.025). Group 2 patients had SF median of 1018 ng/ml (range 250-6300 ng/ml), and Group 3 patients were notable for lower SF levels with SF median of 480 ng/ml (range 15-1500 ng/ml). Significant differences recorded when comparing Group 1 SF levels of and Group 2 patients data (p = 0.004) as well as Group 2 and Group 3 patients SF levels (p = 0.014).
Summary
It was discovered that iron metabolism disorders have been detected in almost all AA patients prior to immunosupressive therapy start and then progressed in time of ongoing RBC transfusions. Notable high SF levels of maintained for a long time after patients became transfusion independent. These data suggest chelation therapy is valuable not only for transfusion dependent AA patients but may also be useful in remission patients with retained laboratory signs of iron overload.
Keyword(s): Aplastic anemia, Chelation, Ferritin
Type: Publication Only
Background
Iron metabolism disorders in patients with AA are not only related to disease pathogenesis but to regular red blood cells (RBC) transfusions.
Aims
Analyze iron parameters before immunosupressive therapy, in time of it (meaning RBC transfusions dependence retained) and in remission phase.
Methods
A total of 85 patients from 18 to 65 years old were enrolled: 41 males and 44 females at age from 18 to 65 years old. Patients were followed up from 1 month to 3 years. Severe forms of AA were detected in 59 patients, non-severe in 26 pts. All patients received immunosupressive therapy (ATG + cyclosporine). Serum ferritin level (SF) was applied as the main iron overload (IOL) indicator (N 11-160 ng/ml). Depending on obtained results all patients were divided into 3 groups. Group 1 patients had SF evaluation prior to combined immunosupressive therapy (n = 47), these patients were split into subgroups 1A and 1B: 1A subgroup patients (n = 16) received < 20 transfusions in 1-4 months prior to the study, 1B subgroup patients (n = 31) received > 20 transfusions in 2-19 months prior to the study. Group 2 patients (n = 20) retained long term RBC transfusion dependence in spite of continued immunosupressive therapy. Group 3 patients (n = 20) demonstrated good immunosuppressive therapy response, therefore developed significant hematological improvement and became transfusion independent.
Results
In patients of 1A subgroup SF median was 303 ng/ml (range 40-1483 ng/ml), in 1B Group - 722 ng/ml (range 105-4950 ng/ml) with significant difference between SF levels received (p = 0.025). Group 2 patients had SF median of 1018 ng/ml (range 250-6300 ng/ml), and Group 3 patients were notable for lower SF levels with SF median of 480 ng/ml (range 15-1500 ng/ml). Significant differences recorded when comparing Group 1 SF levels of and Group 2 patients data (p = 0.004) as well as Group 2 and Group 3 patients SF levels (p = 0.014).
Summary
It was discovered that iron metabolism disorders have been detected in almost all AA patients prior to immunosupressive therapy start and then progressed in time of ongoing RBC transfusions. Notable high SF levels of maintained for a long time after patients became transfusion independent. These data suggest chelation therapy is valuable not only for transfusion dependent AA patients but may also be useful in remission patients with retained laboratory signs of iron overload.
Keyword(s): Aplastic anemia, Chelation, Ferritin
Abstract: PB1703
Type: Publication Only
Background
Iron metabolism disorders in patients with AA are not only related to disease pathogenesis but to regular red blood cells (RBC) transfusions.
Aims
Analyze iron parameters before immunosupressive therapy, in time of it (meaning RBC transfusions dependence retained) and in remission phase.
Methods
A total of 85 patients from 18 to 65 years old were enrolled: 41 males and 44 females at age from 18 to 65 years old. Patients were followed up from 1 month to 3 years. Severe forms of AA were detected in 59 patients, non-severe in 26 pts. All patients received immunosupressive therapy (ATG + cyclosporine). Serum ferritin level (SF) was applied as the main iron overload (IOL) indicator (N 11-160 ng/ml). Depending on obtained results all patients were divided into 3 groups. Group 1 patients had SF evaluation prior to combined immunosupressive therapy (n = 47), these patients were split into subgroups 1A and 1B: 1A subgroup patients (n = 16) received < 20 transfusions in 1-4 months prior to the study, 1B subgroup patients (n = 31) received > 20 transfusions in 2-19 months prior to the study. Group 2 patients (n = 20) retained long term RBC transfusion dependence in spite of continued immunosupressive therapy. Group 3 patients (n = 20) demonstrated good immunosuppressive therapy response, therefore developed significant hematological improvement and became transfusion independent.
Results
In patients of 1A subgroup SF median was 303 ng/ml (range 40-1483 ng/ml), in 1B Group - 722 ng/ml (range 105-4950 ng/ml) with significant difference between SF levels received (p = 0.025). Group 2 patients had SF median of 1018 ng/ml (range 250-6300 ng/ml), and Group 3 patients were notable for lower SF levels with SF median of 480 ng/ml (range 15-1500 ng/ml). Significant differences recorded when comparing Group 1 SF levels of and Group 2 patients data (p = 0.004) as well as Group 2 and Group 3 patients SF levels (p = 0.014).
Summary
It was discovered that iron metabolism disorders have been detected in almost all AA patients prior to immunosupressive therapy start and then progressed in time of ongoing RBC transfusions. Notable high SF levels of maintained for a long time after patients became transfusion independent. These data suggest chelation therapy is valuable not only for transfusion dependent AA patients but may also be useful in remission patients with retained laboratory signs of iron overload.
Keyword(s): Aplastic anemia, Chelation, Ferritin
Type: Publication Only
Background
Iron metabolism disorders in patients with AA are not only related to disease pathogenesis but to regular red blood cells (RBC) transfusions.
Aims
Analyze iron parameters before immunosupressive therapy, in time of it (meaning RBC transfusions dependence retained) and in remission phase.
Methods
A total of 85 patients from 18 to 65 years old were enrolled: 41 males and 44 females at age from 18 to 65 years old. Patients were followed up from 1 month to 3 years. Severe forms of AA were detected in 59 patients, non-severe in 26 pts. All patients received immunosupressive therapy (ATG + cyclosporine). Serum ferritin level (SF) was applied as the main iron overload (IOL) indicator (N 11-160 ng/ml). Depending on obtained results all patients were divided into 3 groups. Group 1 patients had SF evaluation prior to combined immunosupressive therapy (n = 47), these patients were split into subgroups 1A and 1B: 1A subgroup patients (n = 16) received < 20 transfusions in 1-4 months prior to the study, 1B subgroup patients (n = 31) received > 20 transfusions in 2-19 months prior to the study. Group 2 patients (n = 20) retained long term RBC transfusion dependence in spite of continued immunosupressive therapy. Group 3 patients (n = 20) demonstrated good immunosuppressive therapy response, therefore developed significant hematological improvement and became transfusion independent.
Results
In patients of 1A subgroup SF median was 303 ng/ml (range 40-1483 ng/ml), in 1B Group - 722 ng/ml (range 105-4950 ng/ml) with significant difference between SF levels received (p = 0.025). Group 2 patients had SF median of 1018 ng/ml (range 250-6300 ng/ml), and Group 3 patients were notable for lower SF levels with SF median of 480 ng/ml (range 15-1500 ng/ml). Significant differences recorded when comparing Group 1 SF levels of and Group 2 patients data (p = 0.004) as well as Group 2 and Group 3 patients SF levels (p = 0.014).
Summary
It was discovered that iron metabolism disorders have been detected in almost all AA patients prior to immunosupressive therapy start and then progressed in time of ongoing RBC transfusions. Notable high SF levels of maintained for a long time after patients became transfusion independent. These data suggest chelation therapy is valuable not only for transfusion dependent AA patients but may also be useful in remission patients with retained laboratory signs of iron overload.
Keyword(s): Aplastic anemia, Chelation, Ferritin
{{ help_message }}
{{filter}}